Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 30, 2015 12:10 AM ET


Company Overview of NovaDigm Therapeutics, Inc.

Company Overview

NovaDigm Therapeutics, Inc. develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. NovaDigm Therapeutics, Inc. was founded in 2005 and is based in Grand Forks, North Dakota.

4201 James Ray Drive

REAC 1 Building

Suite 2200

Grand Forks, ND 58202

United States

Founded in 2005





Key Executives for NovaDigm Therapeutics, Inc.

Chief Executive Officer and Director
Vice President of Corporate Development
Scientific Founder
Scientific Founder
Scientific Founder
Compensation as of Fiscal Year 2015.

NovaDigm Therapeutics, Inc. Key Developments

NovaDigm Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-18-2015 01:00 PM

NovaDigm Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-18-2015 01:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Timothy Cooke, Chief Executive Officer and Director.

NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis (RVVC)

NovaDigm Therapeutics announced the initiation of a Phase 1b/2a clinical trial to evaluate its NDV-3 vaccine in preventing episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC). The trial is a multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and efficacy of NDV-3. NDV-3 is a vaccine being developed for the treatment and prevention of infections caused by the fungus Candida and the bacterium Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus, or MRSA). NDV-3 is the first vaccine to demonstrate preclinical 'cross-kingdom' protective efficacy against both fungal and bacterial pathogens. The Phase 1b/2a trial will enroll 189 patients at multiple centers in the United States. The objectives of the study are to estimate the effect of a single, intramuscularly-administered dose of NDV-3, as compared to placebo, by evaluating safety and tolerability, as well as humoral and cellular immune responses, over a 12-month period. In addition to these objectives, the study will summarize recurrence of VVC over both a six- and 12-month period, time-to-onset of first VVC episode and severity of subsequent VVC episodes. A summary of the study can be found on the United States National Institutes of Health website, identifier number NCT01926028.

Similar Private Companies By Industry

Company Name Region
Specialty Pharmacy of St. Louis, LLC United States
Galera Therapeutics, Inc. United States
FemmePharma Holding Company, Inc. United States
Genesis Pharmaceutical, Inc. United States
Seldar Pharma, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NovaDigm Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at